Flu
Vaccine Development : A/H1N1 and H5N1 Subtypes, and Seasonal Influenza
BioJENC has identified specific peptides which may play critical
roles in receptor binding specificity and cell entry for A/H1N1, H5N1 and seasonal influenza viruses. We have designed specific
peptides for use in H5N1 and A/H1N1 vaccine developments. These peptide vaccines are being produced for Phase 1 testing in
collaboration with CDC scientists at the Influenza Division to determine the feasibility of developing a novel peptide vaccine
against a potential A/H1N1 and/or H5N1 influenza pandemic strain. The preliminary results from vaccinated mice showed that
BIOJENC H5N1 peptide vaccine is immunogenic and able to induce neutralizing antibody against a highly pathogenic H5N1 human
isolate. Contact us for more information.
October 8, 2007: BioJENC and Louisiana Emerging Technology Center (LETC) co-sponsored
a seminar presented by Dr. Terrence Tumpey, Senior Microbiologist at the Influenza Division of the Centers for Disease Control
and Prevention, on "Pathogenicity and Transmissibility of the 1918 Influenza Virus in Mice and Ferrets." Dr. Juliette Tina
Stefanski, M.D., Regional Administrator/Medical Director of Louisiana Office of Public Health Region IV, also presented a
seminar on "Pandemic Flu: History, Current Status and Prevention." Both public seminars were held at the Louisiana Emerging
Technology Center in Baton Rouge, Louisiana.
